Literature DB >> 25736126

[Application of dexmedetomidine combined with propofol in patients undergoing painless colonoscopy for colonic polyps resection under Narcotrend monitoring].

Jinquan Ji1, Gang Wang, Ke Sun, Guobin Zhou, Zhipeng Wang, Yan Wang.   

Abstract

OBJECTIVE: This clinical study was conducted to investigate the effects of dexmedetomidine (DEX) combined with propofol on vital signs and anaesthetic depth in patients.
METHODS: Ninety patients with ASA 1-2 requiring painless colonoscopy for colonic polyps resection were randomized to receive DEX 0.3 micro;g/kg (group D, n=45) followed by propofol 1 mg/kg or propofol 2 mg/kg (group C, n=45), and according to the body activity and operation time, additional doses of propofol (0.2-0.5 mg/kg) were given. The full recovery time, operation time, consumed dose of propofol, mean arterial pressure (MAP), heart rate (HR), hemoglobin oxygen saturation levels(SPO₂) and NTI were recorded.
RESULTS: The SPO₂recover time and the consumed dose of propofol in group D were decreased compared to those in group C (P<0.01). The rate of the body activity in group D was lower than that in group C (P<0.05). The NTI in group C was lower than that in group D (P<0.05). The HR and MAP were similar in both groups.
CONCLUSION: Under Narcotrend monitoring, the value of DEX combined with low dose of propofol in colonoscopy for colonic polyps resection is to reach more reasonable depth of anesthesia to reduce adverse responses and the dose of propofol.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25736126

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  1 in total

1.  Systematic review and meta-analysis of the prognostic value of Narcotrend monitoring of different depths of anesthesia and different Bispectral Index (BIS) values for cognitive dysfunction after tumor surgery in elderly patients.

Authors:  Xinhua Shi; Xiangnan Chen; Jun Ni; Yanqing Zhang; Hui Liu; Chuan Xu; Hao Wang
Journal:  Ann Transl Med       Date:  2022-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.